AU2002348996B2 - Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder - Google Patents
Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder Download PDFInfo
- Publication number
- AU2002348996B2 AU2002348996B2 AU2002348996A AU2002348996A AU2002348996B2 AU 2002348996 B2 AU2002348996 B2 AU 2002348996B2 AU 2002348996 A AU2002348996 A AU 2002348996A AU 2002348996 A AU2002348996 A AU 2002348996A AU 2002348996 B2 AU2002348996 B2 AU 2002348996B2
- Authority
- AU
- Australia
- Prior art keywords
- org
- estra
- propynyl
- benzodioxol
- dien
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000024714 major depressive disease Diseases 0.000 title claims description 14
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 46
- 229960000890 hydrocortisone Drugs 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000001629 suppression Effects 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- PIVXDCQLELTTCS-HKBOAZHASA-N (8s,13s,14s)-13-but-2-ynyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(CC#CC)CC2 PIVXDCQLELTTCS-HKBOAZHASA-N 0.000 claims 1
- DFELGYQKEOCHOA-BZAFBGKRSA-N (8s,11r,13s,14s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-BZAFBGKRSA-N 0.000 abstract description 25
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 abstract description 6
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
- 208000020401 Depressive disease Diseases 0.000 abstract description 3
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract description 3
- 230000001430 anti-depressive effect Effects 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 10
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 8
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229960003248 mifepristone Drugs 0.000 description 8
- 229960002296 paroxetine Drugs 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 7
- 229940005513 antidepressants Drugs 0.000 description 7
- 239000003862 glucocorticoid Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 5
- 101800000414 Corticotropin Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 4
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229940127421 Glucocorticoid Synthesis Inhibitors Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010048675 Pituitary enlargement Diseases 0.000 description 1
- 206010035104 Pituitary tumour Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002800 anti-glucocorticoid effect Effects 0.000 description 1
- 230000001838 anti-progestagenic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- -1 ketoconozole Chemical compound 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004465 metyrapone Drugs 0.000 description 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 229940023942 remeron Drugs 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204072.1 | 2001-10-26 | ||
| EP01204072 | 2001-10-26 | ||
| PCT/EP2002/011732 WO2003037354A1 (en) | 2001-10-26 | 2002-10-21 | USE OF (11β, 17β)-11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002348996A1 AU2002348996A1 (en) | 2003-07-10 |
| AU2002348996B2 true AU2002348996B2 (en) | 2008-06-05 |
Family
ID=8181136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002348996A Ceased AU2002348996B2 (en) | 2001-10-26 | 2002-10-21 | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040266863A1 (enExample) |
| EP (2) | EP1441739B1 (enExample) |
| JP (1) | JP4647909B2 (enExample) |
| KR (1) | KR20050038580A (enExample) |
| CN (1) | CN100531738C (enExample) |
| AT (2) | ATE317700T1 (enExample) |
| AU (1) | AU2002348996B2 (enExample) |
| BR (1) | BR0213466A (enExample) |
| CA (1) | CA2463446C (enExample) |
| CY (1) | CY1110173T1 (enExample) |
| DE (2) | DE60209248D1 (enExample) |
| DK (1) | DK1652526T3 (enExample) |
| EC (1) | ECSP045080A (enExample) |
| ES (1) | ES2319563T3 (enExample) |
| HR (1) | HRP20040370B1 (enExample) |
| HU (1) | HUP0500070A3 (enExample) |
| IL (2) | IL161248A0 (enExample) |
| IS (1) | IS2702B (enExample) |
| MX (1) | MXPA04003781A (enExample) |
| NO (1) | NO332978B1 (enExample) |
| NZ (1) | NZ532429A (enExample) |
| PL (1) | PL206687B1 (enExample) |
| PT (1) | PT1652526E (enExample) |
| RU (1) | RU2302245C2 (enExample) |
| WO (1) | WO2003037354A1 (enExample) |
| ZA (1) | ZA200403088B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050080061A1 (en) * | 2003-07-23 | 2005-04-14 | Corcept Therapeutics, Inc. | Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| AU2011236053B2 (en) * | 2004-11-19 | 2014-06-26 | Merck Sharpe & Dohme B.V. | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| EP2292269A3 (en) * | 2004-11-19 | 2011-08-10 | N.V. Organon | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| CA2649894A1 (en) * | 2006-05-02 | 2007-11-15 | Corcept Therapeutics, Inc. | The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2 |
| WO2012106514A2 (en) * | 2011-02-03 | 2012-08-09 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| EP2699245A4 (en) * | 2011-04-18 | 2014-12-10 | Pop Test Cortisol Llc | TREATMENT AGAINST HAIR LOSS |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| EP0763541A1 (en) * | 1995-08-17 | 1997-03-19 | Akzo Nobel N.V. | 11-(Substituted phenyl)-estra-4,9-diene derivatives |
| WO1999001779A2 (de) * | 1997-06-30 | 1999-01-14 | Forschungszentrum Jülich GmbH | Magnetflusssensor mit ringförmiger sonde |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4447401A1 (de) * | 1994-12-23 | 1996-07-04 | Schering Ag | 14,17-C¶2¶-überbrückte Steroide |
| CN1528315A (zh) * | 1997-10-06 | 2004-09-15 | ������˹̹�������ѧ�й�ίԱ�� | 治疗糖皮质素功能失调相关性精神病的方法 |
| CN1556709A (zh) * | 2001-03-23 | 2004-12-22 | �Ƹ��� | 使用糖皮质激素受体特效拮抗剂治疗压力症的方法 |
| IL158744A0 (en) * | 2001-05-04 | 2004-05-12 | Corcept Therapeutics Inc | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| MXPA04001893A (es) * | 2001-08-31 | 2005-03-07 | Corcept Therapeutics Inc | Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down. |
-
2002
- 2002-10-21 CA CA2463446A patent/CA2463446C/en not_active Expired - Fee Related
- 2002-10-21 JP JP2003539697A patent/JP4647909B2/ja not_active Expired - Fee Related
- 2002-10-21 CN CNB028210417A patent/CN100531738C/zh not_active Expired - Fee Related
- 2002-10-21 EP EP02781273A patent/EP1441739B1/en not_active Expired - Lifetime
- 2002-10-21 WO PCT/EP2002/011732 patent/WO2003037354A1/en not_active Ceased
- 2002-10-21 AT AT02781273T patent/ATE317700T1/de active
- 2002-10-21 HU HU0500070A patent/HUP0500070A3/hu unknown
- 2002-10-21 AT AT06101005T patent/ATE420649T1/de active
- 2002-10-21 PT PT06101005T patent/PT1652526E/pt unknown
- 2002-10-21 DE DE60209248T patent/DE60209248D1/de not_active Expired - Lifetime
- 2002-10-21 BR BR0213466-7A patent/BR0213466A/pt not_active IP Right Cessation
- 2002-10-21 EP EP06101005A patent/EP1652526B1/en not_active Expired - Lifetime
- 2002-10-21 DE DE60230936T patent/DE60230936D1/de not_active Expired - Lifetime
- 2002-10-21 NZ NZ532429A patent/NZ532429A/en not_active IP Right Cessation
- 2002-10-21 RU RU2004116082/15A patent/RU2302245C2/ru not_active IP Right Cessation
- 2002-10-21 US US10/493,981 patent/US20040266863A1/en not_active Abandoned
- 2002-10-21 MX MXPA04003781A patent/MXPA04003781A/es active IP Right Grant
- 2002-10-21 HR HRP20040370AA patent/HRP20040370B1/xx not_active IP Right Cessation
- 2002-10-21 ES ES06101005T patent/ES2319563T3/es not_active Expired - Lifetime
- 2002-10-21 KR KR1020047006050A patent/KR20050038580A/ko not_active Ceased
- 2002-10-21 IL IL16124802A patent/IL161248A0/xx unknown
- 2002-10-21 PL PL369261A patent/PL206687B1/pl not_active IP Right Cessation
- 2002-10-21 AU AU2002348996A patent/AU2002348996B2/en not_active Ceased
- 2002-10-21 DK DK06101005T patent/DK1652526T3/da active
-
2004
- 2004-03-31 IS IS7204A patent/IS2702B/is unknown
- 2004-04-01 IL IL161248A patent/IL161248A/en not_active IP Right Cessation
- 2004-04-22 ZA ZA200403088A patent/ZA200403088B/en unknown
- 2004-04-23 EC EC2004005080A patent/ECSP045080A/es unknown
- 2004-04-23 NO NO20041651A patent/NO332978B1/no not_active IP Right Cessation
-
2009
- 2009-02-02 CY CY20091100116T patent/CY1110173T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| EP0763541A1 (en) * | 1995-08-17 | 1997-03-19 | Akzo Nobel N.V. | 11-(Substituted phenyl)-estra-4,9-diene derivatives |
| WO1999001779A2 (de) * | 1997-06-30 | 1999-01-14 | Forschungszentrum Jülich GmbH | Magnetflusssensor mit ringförmiger sonde |
Non-Patent Citations (1)
| Title |
|---|
| Journal of Psychiatry and Neuroscience 18(5) (1993) pp 209-213 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nieman et al. | Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486 | |
| EP2211845B1 (en) | Glucocorticoid receptor antagonists such as mifepristone for treating cushing's syndrome | |
| GAILLARD et al. | RU 486 inhibits peripheral effects of glucocorticoids in humans | |
| EP2078032B1 (en) | Compositions and methods for suppressing endometrial proliferation | |
| EP1408981B1 (en) | Methods for preventing antipsychotic-induced weight gain | |
| AU2002348996B2 (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder | |
| EP1567167A2 (en) | Methods for treating gastroesophageal reflux disease | |
| US8193172B2 (en) | Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists | |
| US6696432B1 (en) | Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men | |
| Rapkin et al. | Oral contraceptives and neuroactive steroids | |
| AU2002348996A1 (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder | |
| HK1087357B (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder | |
| LU506495B1 (en) | 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS | |
| US20090118253A1 (en) | Compositions and methods for treating dysfunctional uterine bleeding |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: N.V. ORGANON Free format text: FORMER APPLICANT(S): AKZO NOBEL N.V. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: POP TEST CORTISOL LLC Free format text: FORMER OWNER WAS: N.V. ORGANON |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |